Recurrent endometrial cancer

Clinical Obstetrics and Gynecology

Volumn 54, Issue 2, 2011, Pages 266-277

  Del Carmen, Marcela G ^a   Boruta, David M ^a   Schorge, John O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biological agents; cytoreductive surgery; Endometrial cancer; management; recurrent

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; GEFITINIB; GESTAGEN; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IXABEPILONE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE; MEGESTROL ACETATE; OXALIPLATIN; PACLITAXEL; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS;

ABDOMINAL RADIOTHERAPY; ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CLEAR CELL CARCINOMA; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; GYNECOLOGIC CANCER; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; OVARY CANCER; PAIN; RECURRENT CANCER; THROMBOEMBOLISM; UTERUS SARCOMA;

BIOLOGICAL THERAPY; CARCINOMA; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PELVIS;

EID: 79955569301     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318218c6d1     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010. [Epub ahead of print].
2. Greer BE, Koh WJ, Abu-Rustum N, et al. Uterine neoplasms: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:498-531.
3. Boruta DM II, Gehrig PA, Fader AN, et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142-153.
4. Olawaiye AB, Boruta DM II. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;113:277-283.
5. Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89: 201-209. (Pubitemid 36457866)
6. Barakat RR, Goldman NA, Patel DA, et al. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol. 1999; 75:99-102. (Pubitemid 29477809)
7. Dowdy SC, Mariani A, Cliby WA, et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol. 2006;101: 280-286.
8. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118:14-18.
9. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a doseresponse study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17: 1736-1744. (Pubitemid 29269242)
10. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19:364-367. (Pubitemid 32112847)
11. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92:4-9. (Pubitemid 38147364)
12. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:10-14. (Pubitemid 38147365)
13. McMeekin DS, Gordon A, Fowler J, et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol. 2003; 90:64-69. (Pubitemid 37338077)
14. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18:409-420. (Pubitemid 46359618)
15. Fleming GF, Brunetto VL, Celia D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:2159-2166. (Pubitemid 41095150)
16. Sovak MA, Dupont J, Hensley JL, et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer. 2007;17:197-203. (Pubitemid 46213991)
17. Bose D, Meric-Bernstam F, Hofstetter W, et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010;11:373-382.
18. Oza AM, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-77) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160-J Clin Oncol. 2006
19. ASCO Annual Meeting Proceedings Part I Vol 24, No. 18S, 2006, Abstract # 3003
20. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010. [Epub ahead of print].
21. Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. 2006
22. ASCO Annual Meeting Proceedings Part I Vol 25, No. 18S, 2007, Abstract # 5516.